Akebia's Vafseo Revenue Surges as Rare Kidney Disease Pipeline Advances
Event summary
- Vafseo net product revenues grew to $21.3 million in Q2 2026, a 34% increase over Q1.
- Phase 2 open-label basket trial of ebribafusp initiated for IgA nephropathy, lupus nephritis, and C3 glomerulopathy.
- VOICE trial interim analysis showed statistically significant improved safety outcomes for Vafseo versus ESAs.
- Total revenues decreased to $49.1 million in Q2 2026 from $62.5 million in Q2 2025 due to Auryxia revenue decline.
The big picture
Akebia is navigating a transition phase, with Vafseo showing promising commercial traction while Auryxia revenues decline due to generic competition. The company's focus on advancing its rare kidney disease pipeline positions it in a growing segment of the biopharmaceutical market, but execution risks remain as it balances commercial and R&D investments.
What we're watching
- Commercial Momentum
- Whether Akebia can sustain Vafseo's sequential revenue growth amid competition.
- Pipeline Progress
- The pace at which ebribafusp Phase 2 trial data will influence rare kidney disease strategy.
- Regulatory Strategy
- How the VOICE trial results will impact Vafseo's pathway to becoming standard of care.
Related topics